Investor Presentation Q1 2023
12
Investor presentation
First three months of 2023
R&D milestones
Novo NordiskⓇ
Project
Q1 2023
Q2 2023
Clinical milestones¹
Regulatory milestones¹
H2 2023
Diabetes care
Insulin Icodec
EU/US/CN submission
Oral semaglutide (25/50mg)
FDC semaglutide/GIP OW
Oral GLP-1/GIP
Phase 3 results
US submission
✓ Phase 2 results
✓ Phase 1 results
Obesity care
Rare disease
Other serious chronic diseases
Cagrisema T2D
STEP HFPEF
Oral semaglutide (50 mg)
PYY 1875
SELECT CVOT
Oral Amycretin
Sogroya® (Somapacitan)
Concizumab
Ziltivekimab (HFPEF)
Stem cell HF (Heartseed)
Phase 3 results
Phase 3 results
Phase 1/2 results
Phase 3 initiation
Phase 3 results (T2D)
Phase 3 results
Phase 1 results
✓ US approval (GHD)
JP decision (GHD)
CRL received (HwI)
EU decision (GHD)
Phase 3 initiation
✓ Phase 1 initiation
Stem cell Parkinson's disease
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement
✓ Phase 1 initiation
CRL: Complete response letter; CVOT: Cardiovascular Outcomes Trial; EU: European Union; FDC: Fixed dose combination; GHD: Growth Hormone Deficiency; GIP: Gastric inhibitory polypeptide; GLP-1: Glucagon Like Peptide 1; HFPEF: Heart failure with preserved
ejection fraction; HwI: Haemophilia with inhibitors; JP: Japan; OW: once weekly; PYY: Peptide YY; T2D: Type 2 Diabetes Mellitus; US: United States.View entire presentation